by
Brendon Nafziger, DOTmed News Associate Editor | October 06, 2009
Dr. Eric Fung returns
to work at Vermillion
as chief science officer
Eric Fung, M.D., Ph.D., is expected to return to Vermillion, Inc. to be the company's chief science officer, according to a statement issued by the Freemont, Calif.-based company on Friday.
Dr. Fung, one of the minds behind Vermillion's OVA1 blood test for ovarian cancer, recently cleared by the FDA [See DM 10257], was the company's chief science officer, and a vice president, in 2006.
"I am most enthused about rejoining Vermillion as the OVA1 Test represents an important advance in the care of women with ovarian tumors. Additionally, we will now be able to continue to make progress in our other biomarker programs," Dr. Fung tells DOTmed News.
The Johns Hopkins- and Stanford-trained scientist is returning from Roche Molecular Systems, where he served as director of clinical research, and where he conducted a screening trial on cervical cancer involving around 45,000 women, according to Vermillion.
Currently an independent consultant, Dr. Fung will likely take up his position as CSO once Vermillion completes its Chapter 11 bankruptcy restructuring.
